SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system. This event underscores the growing adoption of robotic-assisted cardiac procedures, which offer the potential for smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery. For SS Innovations, the launch represents a strategic move into a high-acuity surgical specialty, demonstrating the versatility and reliability of the SSi Mantra platform beyond general surgery.
The significance of this announcement lies in its timing and scale. SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This rapid global growth signals increasing acceptance of robotic surgery in emerging markets, where access to advanced medical technology has historically been limited. By enabling complex cardiac procedures in India, SS Innovations is not only tapping into a vast patient population but also positioning itself as a competitor to established players like Intuitive Surgical. The company’s pursuit of U.S. FDA review and European Union CE marking further indicates its ambition to enter highly regulated markets, which could unlock substantial revenue streams and validate its technology on a global scale.
“We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region,” the company wrote in a LinkedIn post (https://ibn.fm/TTTdR). “At SS Innovations International, Inc. we remain committed to enabling hospitals and… Read More”
For investors, the cardiac program at HCG Hospital is more than a clinical milestone; it is a proof point for SS Innovations’ business model. Each new program serves as a reference site that can drive adoption in other hospitals, particularly in India where cardiac disease burdens are high. The company’s ability to train surgeons and proctor procedures—as seen with Dr. Singh and Dr. Malik—is critical for building trust and ensuring successful outcomes. As SS Innovations continues to expand, its progress toward regulatory approvals in the U.S. and Europe will be key catalysts. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. For a deeper look at the company’s strategy and market potential, see the full release on www.newmediawire.com. In an era where healthcare systems are increasingly seeking cost-effective robotic solutions, SS Innovations’ expansion into cardiac surgery could signal a new chapter in the global adoption of surgical robotics.
